geron corp (GERN:NASDAQ GS)
geron corp (GERN) Snapshot
|
Open
$1.10
|
Previous Close
$1.12
|
|
|
Day High
$1.13
|
Day Low
$1.09
|
|
|
52 Week High
09/7/12 - $2.99
|
52 Week Low
12/4/12 - $0.91
|
|
|
Market Cap
146.2M
|
Average Volume 10 Days
569.1K
|
|
|
EPS TTM
$-0.46
|
Shares Outstanding
130.6M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
geron corp (GERN) Related Businessweek News
No Related Businessweek News Foundgeron corp (GERN) Details
Geron Corporation, a biopharmaceutical company, develops therapies for cancer. Its clinical development product candidate includes Imetelstat, a telomerase inhibitor, which is in Phase II clinical trials for the treatment of advanced non-small cell lung cancer, essential thrombocythemia, and multiple myeloma. The company was founded in 1990 and is based in Menlo Park, California.
geron corp (GERN) Top Compensated Officers
geron corp (GERN) Key Developments
Geron Corporation announced that Edward V. Fritzky and Thomas D. Kiley, each a Class II member of the Board of Directors and each a member of the Audit Committee of the Board, retired from the Board, effective as of May 22, 2013, the date of the company’s Annual Meeting of Stockholders. In connection with their retirement, the Board appointed director V. Bryan Lawlis, Ph.D., to the Audit Committee of the Board and Hoyoung Huh, M.D., Ph.D., to the Nominating and Corporate Governance Committee of the Board.
Geron Corporation reported unaudited consolidated earnings results for the first quarter ended March 31, 2013. For the quarter, the company reported loss from operations was $11,985,000 against $18,918,000 a year ago. Net loss was $11,897,000 against $18,739,000 a year ago. Basic and diluted net loss per share was $0.09 against $0.15 a year ago. Operating Revenue was $0.765 million compared to $1.3 million for the comparable 2012 period.
Geron Corporation, Q1 2013 Earnings Call, Apr 26, 2013
| Recently Viewed | |||
| GERN:US | $1.12 USD | 0.00 |  |
| Company | Last | Change |
| Advanced Cell Technology Inc | $0.07 USD | +0.0005 |
| Athersys Inc | $1.74 USD | -0.07 |
| Cytori Therapeutics Inc | $2.50 USD | -0.07 |
| Neostem Inc | $0.59 USD | +0.02 |
| StemCells Inc | $1.83 USD | -0.05 |
| View Industry Companies | ||
Industry Analysis
GERN
Industry Average
| Valuation | GERN | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 64.6x |
|
| Price/Book | 1.9x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 30.2x |
|
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact GERON CORP, please visit www.geron.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
